​

Divi's Laboratories Limited

NSEI:DIVISLAB Stock Report

Market Cap: ₹1.8t

Divi's Laboratories (DIVISLAB) Stock Overview

Engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. More details

DIVISLAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends4/6

Rewards

Earnings are forecast to grow 18.75% per year

Earnings grew by 36.9% over the past year

Risk Analysis

Dividend of 0.44% is not well covered by free cash flows


DIVISLAB Community Fair Values

Create Narrative

See what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.

DIVISLAB logo
Divi's Laboratories
AN
AnalystHighTarget
AnalystHighTarget
Consensus Narrative from 29 Analysts

Aging Populations And Rising Spending Will Secure Resilient API Manufacturing

Key Takeaways Expanding capacity, advanced technology adoption, and unique supply capabilities position Divi's as a key innovation partner and supply anchor for global pharma, driving durable margin expansion. Strong long-term client relationships and diversification in high-growth markets ensure compounding revenue growth, pricing power, and sustainable competitive advantages.
View narrative
₹7.90k
FV
14.1% undervalued intrinsic discount
22.15%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
1 day ago author updated this narrative
DIVISLAB logo
Divi's Laboratories
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 29 Analysts

The Kakinada Phase I Expansion Will Increase Future Manufacturing Capabilities And Efficiency

Key Takeaways Expansion at Kakinada and backward integration efforts are expected to enhance revenue and net margins through increased manufacturing capabilities and operational efficiency. Growth in the nutraceutical division and custom synthesis business, along with easing price pressures, could stabilize and boost future revenue.
View narrative
₹6.09k
FV
11.4% overvalued intrinsic discount
14.87%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
6 days ago author updated this narrative
DIVISLAB logo
Divi's Laboratories
AN
AnalystLowTarget
AnalystLowTarget
Consensus Narrative from 29 Analysts

Global Regulations And Trade Tensions Will Hamper Future Prospects

Key Takeaways Increased compliance costs and shifting industry trends threaten margins and growth, as evolving pharma demands move away from Divi's core small molecule focus. Heavy reliance on limited products and major overseas customers exposes Divi's to revenue instability, margin pressures, and risks from geopolitical disruptions.
View narrative
₹4.53k
FV
49.9% overvalued intrinsic discount
14.16%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
13 days ago author updated this narrative
View Divi's Laboratories Community

Divi's Laboratories Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Divi's Laboratories
Historical stock prices
Current Share Price₹6,790.00
52 Week High₹7,071.50
52 Week Low₹4,395.30
Beta0.34
1 Month Change1.84%
3 Month Change18.00%
1 Year Change48.55%
3 Year Change80.91%
5 Year Change197.51%
Change since IPO76,949.65%

Recent News & Updates

Recent updates

Divi's Laboratories Limited (NSE:DIVISLAB) Investors Are Less Pessimistic Than Expected

Apr 10
Divi's Laboratories Limited (NSE:DIVISLAB) Investors Are Less Pessimistic Than Expected

Divi's Laboratories Limited's (NSE:DIVISLAB) Shareholders Might Be Looking For Exit

Dec 25
Divi's Laboratories Limited's (NSE:DIVISLAB) Shareholders Might Be Looking For Exit
author-image

Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability

Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.

Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)

Sep 06
Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)

Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

Aug 06
Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Jul 19
The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Shareholder Returns

DIVISLABIN Life SciencesIN Market
7D-2.1%-0.7%-0.9%
1Y48.6%33.9%-3.2%

Return vs Industry: DIVISLAB exceeded the Indian Life Sciences industry which returned 33.9% over the past year.

Return vs Market: DIVISLAB exceeded the Indian Market which returned -3.2% over the past year.

Price Volatility

Is DIVISLAB's price volatile compared to industry and market?
DIVISLAB volatility
DIVISLAB Average Weekly Movement3.6%
Life Sciences Industry Average Movement5.6%
Market Average Movement5.7%
10% most volatile stocks in IN Market8.4%
10% least volatile stocks in IN Market3.9%

Stable Share Price: DIVISLAB has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: DIVISLAB's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199010,542Kiran Diviwww.divislabs.com

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products.

Divi's Laboratories Limited Fundamentals Summary

How do Divi's Laboratories's earnings and revenue compare to its market cap?
DIVISLAB fundamental statistics
Market cap₹1.80t
Earnings (TTM)₹21.91b
Revenue (TTM)₹93.60b
82.3x
P/E Ratio
19.3x
P/S Ratio

Is DIVISLAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DIVISLAB income statement (TTM)
Revenue₹93.60b
Cost of Revenue₹39.28b
Gross Profit₹54.32b
Other Expenses₹32.41b
Earnings₹21.91b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)82.53
Gross Margin58.03%
Net Profit Margin23.41%
Debt/Equity Ratio0.01%

How did DIVISLAB perform over the long term?

See historical performance and comparison

Dividends

0.4%
Current Dividend Yield
36%
Payout Ratio

Does DIVISLAB pay a reliable dividends?

See DIVISLAB dividend history and benchmarks
When do you need to buy DIVISLAB by to receive an upcoming dividend?
Divi's Laboratories dividend dates
Ex Dividend DateJul 25 2025
Dividend Pay DateSep 10 2025
Days until Ex dividend9 days
Days until Dividend pay date56 days

Does DIVISLAB pay a reliable dividends?

See DIVISLAB dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/15 20:11
End of Day Share Price 2025/07/15 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Divi's Laboratories Limited is covered by 53 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
Ashwin MehtaAmbit Capital